

Product Information Sheet for NR-9401

***Bacillus anthracis*, Strain Sterne BA781 (Δ lef243/ Δ cya244/ Δ pagA242)**

Catalog No. NR-9401

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

E. Scott Stibitz, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland.

Manufacturer:

NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH

Product Description:

Bacteria Classification: *Bacillaceae*, *Bacillus*, *Bacillus cereus* group

Species: *Bacillus anthracis*

Strain: Sterne BA781 (Δ lef243/ Δ cya244/ Δ pagA242) Note: The designation BA781 refers to the numbering system used in the Stibitz laboratory.

Original Source: *Bacillus anthracis* (*B. anthracis*), strain Sterne BA781 (Δ lef243/ Δ cya244/ Δ pagA242) and the other mutant strains listed in the table below are derivatives of *B. anthracis*, strain Sterne 7702.¹ The Sterne BA781 (Δ lef243/ Δ cya244/ Δ pagA242) strain is a triple deletion mutant.¹

Comment: The complete genome of *B. anthracis*, strain Sterne has been sequenced (GenBank: [AE017225](#)).²

BEI Resources #	Sterne Strain	Stibitz Lab Number
NR-9397	lef mutant	BA723
NR-9398	cya mutant	BA695
NR-9399	pag mutant	BA690
NR-9400	lef/cya mutant	BA721
NR-9401	lef/cya/pag mutant	BA781

B. anthracis is an aerobic, Gram-positive, spore-forming, rod-shaped bacillus that causes the acute infectious disease anthrax. Herbivores are the natural hosts and become infected by consuming soil. Humans are incidentally infected by coming into contact with infected animals or their products. *B. anthracis* virulence is dependent on the possession of two large plasmids, pXO1 and pXO2, which are responsible for the expression of an extracellular toxin and a polysaccharide capsule, respectively. The extracellular toxin is composed of three proteins: lethal factor, edema factor, and protective antigen.³

The presence of pXO1 (but absence of the *lef*, *cya* and *pag* genes) and the absence of pXO2 in NR-9401 have been confirmed by PCR amplification of plasmid-specific sequences from extracted DNA.

Material Provided:

Each vial contains approximately 0.5 mL of bacterial culture in 0.5X Tryptic Soy Broth supplemented with 10% glycerol.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

NR-9401 was packaged aseptically, in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Media:

Tryptic Soy Broth or equivalent

Tryptic Soy Agar with 5% sheep blood, or equivalent

Incubation:

Temperature: 35 to 37°C

Atmosphere: Aerobic with 5% CO₂

Propagation:

1. Keep vial frozen until ready for use; thaw slowly.
2. Transfer the entire thawed aliquot into a single tube of broth.
3. Use several drops of the suspension to inoculate an agar slant and/or plate.
4. Incubate the tubes and plate at 35 to 37°C for 24 hours.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: *Bacillus anthracis*, Strain Sterne BA781 (Δ lef243/ Δ cya244/ Δ pagA242), NR-9401."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmb15/bmb15toc.htm. This publication recommends that all persons working in or entering laboratory or animal care areas where frequent activities with clinical specimens or diagnostic cultures of *Bacillus anthracis* are being conducted should have documented evidence of satisfactory vaccination.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Janes, B. K. and S. Stibitz. "Routine Markerless Gene Replacement in *Bacillus anthracis*." Infect. Immun. 74 (2006): 1949-1953. PubMed: 16495572.
2. Rasko, D. A., et al. "Genomics of the *Bacillus cereus* Group of Organisms." FEMS Microbiol. Rev. 29 (2005): 303-329. PubMed: 15808746.
3. Oncü, S., S. Oncü and S. Sakarya. "Anthrax-An Overview." Med. Sci. Monit. 9 (2003): RA276-RA283. PubMed: 14586293.
4. Spencer, R. C. "*Bacillus anthracis*." J. Clin. Pathol. 56 (2003): 182-187. PubMed: 12610093.

ATCC® is a trademark of the American Type Culture Collection.

